Immuron Limited, a biopharmaceutical company, focuses on the research and development of polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that produces antibodies to treat various diseases, including infectious diseases, cancers, and chronic inflammatory diseases. The company markets Travelan for the prevention of travellers' diarrhea. Its lead product candidate IMM-124E is in Phase II clinical trials for NASH and ASH. The company has a research and development collaboration agreement with the Walter Reed Army Institute of Research; and Naval Medical Research Center. Immuron Limited was founded in 1994 and is based in Blackburn North, Australia.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMRN
Previous Symbol
CUSIPN/A
Phone61-3-9824-5254
Debt
Debt-to-Equity RatioN/A
Current Ratio8.81
Quick Ratio8.19
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.43 million
Price / Sales904.77
Cash FlowN/A
Price / CashN/A
Book Value$0.05 per share
Price / Book181.23
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees7
Outstanding Shares142,780,000
Market Cap$1.29 billion
OptionableNot Optionable
IMMURON Ltd/S (NASDAQ:IMRN) Frequently Asked Questions
What is IMMURON Ltd/S's stock symbol?
IMMURON Ltd/S trades on the NASDAQ under the ticker symbol "IMRN."
What price target have analysts set for IMRN?
1 brokers have issued 12-month target prices for IMMURON Ltd/S's stock. Their predictions range from $20.00 to $20.00. On average, they anticipate IMMURON Ltd/S's stock price to reach $20.00 in the next year. This suggests a possible upside of 120.7% from the stock's current price. View Analyst Price Targets for IMMURON Ltd/S.
What is the consensus analysts' recommendation for IMMURON Ltd/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMMURON Ltd/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IMMURON Ltd/S.
What are Wall Street analysts saying about IMMURON Ltd/S stock?
Here are some recent quotes from research analysts about IMMURON Ltd/S stock:
- 1. HC Wainwright analysts commented, "Valuation, risks and uncertainties. We have valued Immuron using a sum-of-the-parts approach. IMM-124E has a risk-adjusted net present value (rNPV) of $30M, based on a discount rate of 20% and 20% probability of success (reflecting its focus on an area with a very crowded competitive landscape), while IMM-529 has an rNPV of $36M based on a discount rate of 17.5% and 25% probability of success." (7/25/2018)
- 2. According to Zacks Investment Research, "Immuron Limited is a bio pharmaceutical Microbiome company. It focused on oral immunotherapy using polyclonal antibody products for humans. The company is involved in developing therapeutic products in NASH, ASH and other diseases mediated through gut disbiosis. Immuron Limited is based in Armadale, Australia. " (6/12/2018)
Has IMMURON Ltd/S been receiving favorable news coverage?
Media coverage about IMRN stock has been trending positive recently, according to InfoTrie. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IMMURON Ltd/S earned a daily sentiment score of 2.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the next few days.
Who are some of IMMURON Ltd/S's key competitors?
Some companies that are related to IMMURON Ltd/S include Loxo Oncology (LOXO), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), Agios Pharmaceuticals (AGIO), Horizon Pharma (HZNP), FibroGen (FGEN), Array Biopharma (ARRY), Emergent Biosolutions (EBS), Ligand Pharmaceuticals (LGND), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Endo International (ENDP) and Madrigal Pharmaceuticals (MDGL).
Who are IMMURON Ltd/S's key executives?
IMMURON Ltd/S's management team includes the folowing people:
- Dr. Jerry Kanellos Ph.D., Interim CEO and Chief Operating & Scientific Officer (Age 57)
- Mr. Peter Anastasiou, Exec. Vice Chairman (Age 58)
- Mr. Phillip Allen Hains, Joint CFO & Company Sec. (Age 59)
- Mr. David Lyon, Head of Marketing
- Mr. Reza Moussakhani MEng(CP), GrdCertEngMgt,BScChem,DipBusFM, Manufacturing Quality Director
When did IMMURON Ltd/S IPO?
(IMRN) raised $6 million in an IPO on Friday, June 9th 2017. The company issued 600,000 shares at a price of $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) acted as the underwriters for the IPO and WallachBeth Capital was co-manager.
How do I buy shares of IMMURON Ltd/S?
Shares of IMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IMMURON Ltd/S's stock price today?
One share of IMRN stock can currently be purchased for approximately $9.0616.
How big of a company is IMMURON Ltd/S?
IMMURON Ltd/S has a market capitalization of $1.29 billion and generates $1.43 million in revenue each year. IMMURON Ltd/S employs 7 workers across the globe.
What is IMMURON Ltd/S's official website?
How can I contact IMMURON Ltd/S?
IMMURON Ltd/S's mailing address is 25 37 CHAPMAN STREET, VICTORIA C3, 3130. The company can be reached via phone at 61-3-9824-5254 or via email at [email protected]
MarketBeat Community Rating for IMMURON Ltd/S (NASDAQ IMRN)
MarketBeat's community ratings are surveys of what our community members think about IMMURON Ltd/S and other stocks. Vote "Outperform" if you believe IMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
